McCann Healthcare names four as co-CEOs

Share this article:
McCann Healthcare names four as co-CEOs
McCann Healthcare names four as co-CEOs
McCann Healthcare Worldwide announced a new “Office of the CEO” under which four executives will share leadership responsibility.

The realignment follows the December departure of McCann Healthcare chief Richard Nordstrom, who had held that post since 2005.

The four execs, who will take on responsibility for leading the network in addition to leading their units, are: Marci Piasecki, CEO of Torre Lazur Healthcare Group; Maureen Regan, managing partner of RCW Group; David Backmann, DCFO of McCann Healthcare Worldwide; and John Cahill, president, McCann Healthcare EMEA and Asia Pacific as well as head of med ed.

Cahill, who is based in London, will be first among equals, serving as chairman of the Office of the CEO, with oversight for global operations as well as multinational coordination on behalf of clients, the company said, and will serve as “the single point of contact for the McCann Healthcare Worldwide Network,” though different companies will have different point persons among the four.

McCann Worldgroup chief John Dooner said in a statement: The new structure both recognizes the leadership achievements of the four executives and will help us meet our clients' global needs by fostering increased collaboration between McCann's healthcare companies around the world. We thank Richard for all that he has accomplished and wish him well with his new plans.”

The changes were first reported in the January issue of MM&M.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union